- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. (Pubmed Central) - Oct 12, 2022
Besides, there are about 280 vaccines that are undergoing preclinical and clinical trials including Sputnik-V, Covaxin or BBV152, and NVX-CoV2373...Moreover, we have also summarized the immunological responses and prophylactic efficacy of various COVID-19 vaccine regimens. In this context, this review can give insights into the development of effective vaccines against SARS-CoV-2 and its variants in the future.
- |||||||||| SARS-CoV-2 Breakthrough Infections and its Implications on Booster Vaccination Strategies (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_1453;
From April-September 2021, there were 1,594 breakthrough infections from fully vaccinated personnel with breakdown as follows: 1,404 CoronaVac (Sinovac), 118 ChAdOx1-S (AstraZeneca), 47 Sputnik V (Gamaleya), 20 BNT162b2 (Pfizer-BioNTech), and 5 mRNA-1273 (Moderna)...Higher breakthrough infections are expected if COVID-19 vaccines with lower efficacy are given and if circulating variants have enhanced immune escape abilities. Booster vaccination strategies should consider the best combination of vaccine brand/platform and approach (homologous vs heterologous) which will provide the highest protection for those with higher exposure or higher risk for severe morbidity/mortality.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_918;
Cancer type and active treatment were not predictors of AEs. Table: 426P Conclusions Sputnik V vaccination appears to be safe and tolerable in patients with cancer, however additional studies should be conducted to assess efficacy and safety of the vaccine in cancer setting.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Retrospective data, Review, Journal: The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis. (Pubmed Central) - Oct 5, 2022
This article also briefly covers COVID-19 vaccines available worldwide, specifically their mode of action and effectiveness. Based on the studies published so far, there is no scientific proof of any association between COVID-19 vaccines and fertility impairment in men or women.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Cerebral venous thrombosis associated with COVID-19 (Pubmed Central) - Oct 5, 2022
VITT is a rare side-effect of COVID-19 vaccination that also causes CVT. The article presents an overview of the above problem and a clinical case of a patient with CVT that developed within a month after the first component of the Sputnik V vaccination and COVID-19.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka. (Pubmed Central) - Sep 30, 2022
The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. (Pubmed Central) - Sep 29, 2022
These findings highlight the need for further studies to understand the effects on clinical outcomes. Vaccination against COVID-19 in patients with cirrhosis is effective and safe.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Preclinical, Journal: Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. (Pubmed Central) - Sep 29, 2022
High immunogenic properties of the vaccine were verified in non-human primates (common marmosets) by marked IgG and neutralizing antibody (NtAb) production in blood serum, antigen-specific T-cell proliferation and cytokine release of peripheral blood mononuclear cells (PBMCs) accompanied by formation of IgA antibodies in the nasal mucosa. We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality.We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation.
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Trial completion date, Trial primary completion date: FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - Sep 29, 2022
P2b, N=450, Active, not recruiting,
We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality.We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation. Trial completion date: Jul 2022 --> Jan 2023 | Trial primary completion date: Jun 2022 --> Nov 2022
- |||||||||| BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. (Pubmed Central) - Sep 23, 2022
P=N/A
In this national cohort of patients, the most common vaccines used were Gam-COVID-Vac and ChAdOx1 nCoV-19. A quarter of the patients presented an AE and 5.1% presented SARS-CoV-2 infection after vaccination, in most cases mild.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: The Willingness to get Vaccinated Against SARS-CoV-2 Virus among Southeast Asian Countries: Does the Vaccine Brand Matter? (Pubmed Central) - Sep 22, 2022
The current study uses data surveyed with 2,500 respondents during August and September 2021 in Vietnam, Indonesia, the Philippines and Malaysia to examine the willingness to get vaccinated against SARS-CoV-2 virus with six COVID-19 vaccines...The results indicate that additional scientific evidence on the efficacy and safety of the vaccines is essential for the respondents to decide whether to vaccinate or not. Such evidence can be made available in multiple formats and provided through appropriate channels and vaccination communication campaigns.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Experience of Military Medicine in the Fight against the New Coronavirus Infection. (Pubmed Central) - Sep 14, 2022
Among the priority scientific results of military doctors, especially noteworthy is the study of the world's first COVID-19 vaccine Sputnik V, its immunogenicity, the effectiveness of its use in previously ill patients and revaccination, as well as the use of immune plasma from those who have been ill and vaccinated...They carried out ultrastructural studies of the life cycle of the virus. It is shown that the system of comprehensive measures implemented by military medicine determined a lower incidence of new coronavirus infection among the personnel of the Ministry of Defense of Russia and a lower mortality among the military.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study. (Pubmed Central) - Sep 14, 2022
It is shown that the system of comprehensive measures implemented by military medicine determined a lower incidence of new coronavirus infection among the personnel of the Ministry of Defense of Russia and a lower mortality among the military. The distribution of alleged vaccine efficacies of the Sputnik vaccine by age in the phase-III trial is very unlikely to occur in genuine experimental data, even if the number of patients recruited, vaccine efficacy, and overall infection rate are true and there is no underlying difference in vaccine efficacy by age.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Psoriasis with Sputnik V vaccine, a potential triggering factor. (Pubmed Central) - Sep 10, 2022
The Sputnik V vaccine provided long-term and durable humoral immunity in our cohort specially if a person has been both vaccinated and had a previous infection with SARS-CoV-2. No abstract available
- |||||||||| Clinical, Review, Journal: Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. (Pubmed Central) - Sep 7, 2022
A systematic literature search on MEDLINE, LitCovid and LIVIVO databases was performed for eligible randomized controlled trials, observational studies, registries and case reports that reported on imaging-confirmed acute ischemic stroke in the context of any SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, Ad26.COV2.S, ChAdOx1 or Gam-COVID-Vac...In addition, differences in the likelihood of acute ischemic stroke were found among the vaccines studied, although no overall increased stroke incidence was demonstrated with vaccination. In this systematic review of the available literature, we found that the risk of acute ischemic stroke does not appear to be increased in vaccinated individuals who have received any of the currently licensed SARS-CoV-2 vaccines compared with the baseline incidence of stroke.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM. (Pubmed Central) - Sep 4, 2022
P=N/A
In this systematic review of the available literature, we found that the risk of acute ischemic stroke does not appear to be increased in vaccinated individuals who have received any of the currently licensed SARS-CoV-2 vaccines compared with the baseline incidence of stroke. we found an incidence density of breakthrough COVID-19 infection of 5 × 10.000 patients/day (95%CI 0.7-12) after vaccination in Argentina.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: SARS-CoV-2 antibodies among health care workers from a children's hospital. (Pubmed Central) - Aug 28, 2022
In Argentina, health care workers have been the first ones to receive the COVID-19 vaccine, but there are still few data on the production of anti-S IgG antibodies...Conclusion. We provide data on post-vaccination production of IgG anti-S antibodies among health care workers from a children's hospital and explore some predictors.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Observational data, Journal, Adverse events: Comparison of Side Effects of COVID-19 Vaccines: Sinopharm, AstraZeneca, Sputnik V, and Covaxin in Women in Terms of Menstruation Disturbances, Hirsutism, and Metrorrhagia: A Descriptive-Analytical Cross-Sectional Study. (Pubmed Central) - Aug 28, 2022
Seemingly, Covaxin revealed the most side effects in terms of menstruation disturbances. As a result, professionalsmust carry out several studies with reasonable samples to recommend the vaccine to those women confidently.
- |||||||||| Journal, Adverse events: Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. (Pubmed Central) - Aug 17, 2022
P=N/A
A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2...The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2. ClinicalTrials.gov, identifier NCT05228912.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). (Pubmed Central) - Aug 10, 2022
VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster. The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Vaccination Immune Response Against Sars-Cov-2 In Patients With Autoimmune Rheumatic Diseases (Screen # 1) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_149;
None of the 5 patients with Rituximab showed seroconversion...There were no differences in the serological response between patients with SLE and other rheumatic diseases. Seroconversion and antibody titres levels were associated with type of vaccine applied, being Sinopharm who presented the lowest response.
- |||||||||| BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Sars-Cov-2 Infection After Vaccination In Patients With Rheumatic Diseases In Argentina (Screen # 2) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_147;
At vaccination, most had low disease activity (75%) or were in remission, 19% were on steroids, 39% methotrexate, 27% bDMARDs and 6% JAK inhibitors...Only 8 vaccinated patients (12%) had an unfavorable COVID course; 7 (88%) had incomplete schemes (5 Gam-COVIDVac, 1 ChAdOx1 nCov-19 and 1 BBIBP-CorV) and one patient 2 doses of Gam-COVID-Vac...Patients with at least one vaccine dose had less frequently severe COVID-19 (12% vs 24%, p=0.067) and lower mortality rate (3% vs 6%, p=0.498). Conclusion Only 5% of patients with RD vaccinated for SARS-CoV2 had COVID-19, most mild and 25% were diagnosed after completing the scheme
|
